Search

Author/Creator Webster, Alan

2. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Issue 8 (August 2015)

Authors:
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S K
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
990
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Issue 8 (August 2015)

Authors:
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S K
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
990
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search